Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Kineret GMP Warning Letter Prompts Changes To Internal Amgen Inspections

  • News

Executive Summary

Amgen is making global changes to its internal inspection procedures in response to a warning letter from FDA

You may also be interested in...



Enbrel, Prolia Suffer FDA’s Combination Punch On Device Components

Amgen did not follow proper procedures when it switched from one Enbrel vial adapter to another, FDA says, a change that led to an uptick in product complaints.

GMP Warning Letter Downward Trend Accelerates; Few Oral Solids Get Cited

The number of warning letters issued by FDA to pharmaceutical firms for good manufacturing practices fell by half in fiscal 2003

GMP Warning Letter Downward Trend Accelerates; Few Oral Solids Get Cited

The number of warning letters issued by FDA to pharmaceutical firms for good manufacturing practices fell by half in fiscal 2003

Table

View full table

Tags:
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS042463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By